BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.07 USD | +0.79% |
|
-0.60% | -22.14% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,187 | 15,918 | 16,220 | 19,234 | 18,162 | 14,254 | - | - |
| Enterprise Value (EV) 1 | 14,870 | 15,643 | 15,778 | 19,592 | 18,176 | 13,556 | 12,917 | 12,099 |
| P/E ratio | -650 x | 19.4 x | -252 x | 138 x | 111 x | 40.8 x | 28.7 x | 22.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.91 x | 8.56 x | 8.79 x | 9.18 x | 7.51 x | 5.2 x | 4.62 x | 4.15 x |
| EV / Revenue | 8.73 x | 8.41 x | 8.55 x | 9.35 x | 7.51 x | 4.95 x | 4.19 x | 3.53 x |
| EV / EBITDA | 3,070 x | 229 x | 614 x | 77.9 x | 69.2 x | 26.5 x | 16.4 x | 11.8 x |
| EV / FCF | -154 x | -540 x | 75.5 x | 357 x | 290 x | 25.1 x | 19.5 x | 14.5 x |
| FCF Yield | -0.65% | -0.19% | 1.32% | 0.28% | 0.34% | 3.99% | 5.13% | 6.89% |
| Price to Book | 4.87 x | 3.88 x | 3.8 x | 4.25 x | 3.67 x | 2.61 x | 2.29 x | 1.97 x |
| Nbr of stocks (in thousands) | 179,625 | 181,530 | 183,593 | 185,849 | 188,368 | 189,880 | - | - |
| Reference price 2 | 84.55 | 87.69 | 88.35 | 103.5 | 96.42 | 75.07 | 75.07 | 75.07 |
| Announcement Date | 2/26/20 | 2/25/21 | 2/23/22 | 2/27/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,704 | 1,860 | 1,846 | 2,096 | 2,419 | 2,739 | 3,085 | 3,432 |
| EBITDA 1 | 4.843 | 68.44 | 25.7 | 251.5 | 262.5 | 512.1 | 787.4 | 1,029 |
| EBIT 1 | -100.5 | -36.76 | -82.34 | 149.6 | 158.1 | 450.7 | 685 | 926.1 |
| Operating Margin | -5.9% | -1.98% | -4.46% | 7.14% | 6.54% | 16.46% | 22.2% | 26.99% |
| Earnings before Tax (EBT) 1 | -94.81 | -42.32 | -75.35 | 149.6 | 188.6 | 470.6 | 687.8 | 928.5 |
| Net income 1 | -23.85 | 859.1 | -64.08 | 141.6 | 167.6 | 363.5 | 508.5 | 686.7 |
| Net margin | -1.4% | 46.18% | -3.47% | 6.75% | 6.93% | 13.27% | 16.48% | 20.01% |
| EPS 2 | -0.1300 | 4.530 | -0.3500 | 0.7500 | 0.8700 | 1.839 | 2.614 | 3.394 |
| Free Cash Flow 1 | -96.76 | -28.95 | 209 | 54.94 | 62.57 | 540.4 | 663.1 | 833.4 |
| FCF margin | -5.68% | -1.56% | 11.32% | 2.62% | 2.59% | 19.73% | 21.5% | 24.28% |
| FCF Conversion (EBITDA) | - | - | 813.13% | 21.84% | 23.84% | 105.53% | 84.22% | 80.96% |
| FCF Conversion (Net income) | - | - | - | 38.81% | 37.32% | 148.65% | 130.4% | 121.37% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/25/21 | 2/23/22 | 2/27/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 449.8 | 519.4 | 533.8 | 505.3 | 537.5 | 596.4 | 595.3 | 581.3 | 646.2 | 648.8 | 664.2 | 693.4 | 740.3 | 737.5 | 755.8 |
| EBITDA 1 | - | 164.7 | 64.42 | 22.38 | 0.053 | 85.77 | - | 51.35 | 41.08 | 115.8 | 101 | 79.16 | 127.6 | - | - |
| EBIT 1 | -65.88 | 137.3 | 39.15 | -2.417 | -24.5 | 59.35 | 58.87 | 25.66 | 14.22 | 88.46 | 77.61 | 107.5 | 134.1 | 149.7 | 160.4 |
| Operating Margin | -14.65% | 26.44% | 7.33% | -0.48% | -4.56% | 9.95% | 9.89% | 4.41% | 2.2% | 13.63% | 11.68% | 15.5% | 18.11% | 20.3% | 21.22% |
| Earnings before Tax (EBT) 1 | -66.57 | 134.2 | 34.85 | -1.904 | -17.56 | 56.76 | 70.81 | 41.67 | 19.33 | 105.5 | 94.07 | 118.4 | 143.6 | 159.9 | 171 |
| Net income 1 | -57.9 | 120.8 | 27.66 | -6.652 | -0.249 | 50.85 | 56.04 | 40.38 | 20.38 | 88.66 | 73.11 | 93.64 | 112 | 119.1 | 130 |
| Net margin | -12.87% | 23.26% | 5.18% | -1.32% | -0.05% | 8.53% | 9.41% | 6.95% | 3.15% | 13.66% | 11.01% | 13.5% | 15.14% | 16.15% | 17.21% |
| EPS 2 | -0.3200 | 0.6300 | 0.1500 | -0.0400 | - | 0.2700 | 0.2900 | 0.2100 | 0.1100 | 0.4600 | 0.3496 | 0.4728 | 0.5740 | 0.5819 | 0.6303 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 4/27/22 | 8/3/22 | 10/26/22 | 2/27/23 | 4/26/23 | 7/31/23 | 11/1/23 | 2/22/24 | 4/24/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 358 | 13.2 | - | - | - |
| Net Cash position 1 | 318 | 276 | 443 | - | - | 698 | 1,337 | 2,155 |
| Leverage (Debt/EBITDA) | - | - | - | 1.425 x | 0.0501 x | - | - | - |
| Free Cash Flow 1 | -96.8 | -28.9 | 209 | 54.9 | 62.6 | 540 | 663 | 833 |
| ROE (net income / shareholders' equity) | -0.78% | 23.8% | -1.53% | 3.19% | 3.51% | 8.67% | 11.2% | 12.9% |
| ROA (Net income/ Total Assets) | -0.52% | 16.3% | -1.08% | 2.29% | 2.54% | 6.17% | 8.69% | 9.71% |
| Assets 1 | 4,559 | 5,269 | 5,926 | 6,190 | 6,608 | 5,895 | 5,853 | 7,075 |
| Book Value Per Share 2 | 17.40 | 22.60 | 23.20 | 24.40 | 26.30 | 28.70 | 32.70 | 38.00 |
| Cash Flow per Share 2 | - | 0.4500 | 1.670 | 0.9300 | 0.8300 | 5.870 | 3.930 | - |
| Capex 1 | 145 | 114 | 95.6 | 121 | 96.7 | 102 | 106 | 111 |
| Capex / Sales | 8.51% | 6.14% | 5.18% | 5.77% | 4% | 3.73% | 3.45% | 3.22% |
| Announcement Date | 2/26/20 | 2/25/21 | 2/23/22 | 2/27/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
75.07
USD
Average target price
109.3
USD
Spread / Average Target
+45.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.14% | 14.25B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B |
- Stock Market
- Equities
- BMRN Stock
- Financials BioMarin Pharmaceutical Inc.
